Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (3744)	12/18/2002 6:48:13 PM
From: Icebrg	Read Replies (1) of 10345

Curis is continuing their re-focus campaign. Or shall we call it their survival efforts. A couple of years too late, perhaps. Soon there will only be hedgehogs left. Let's hope that Elan at least looks kindly at that j/v. CAMBRIDGE, Mass., Dec. 18 /PRNewswire-FirstCall/ -- Curis, Inc. (Nasdaq: CRIS - News) announced today it has assigned and licensed Curis patent rights related to the development of cellular therapeutics for the treatment of diabetes to ES Cell International Pte Ltd (ESI), which develops stem cells as therapeutic products for various human disorders. As part of the overall transaction, ESI will assume all responsibility for future development and clinical testing of Curis' diabetes stem-cell technologies and cover FTE costs. This agreement is the latest in a series of transactions reinforcing Curis' efforts to streamline its in-house research and development, and license out non-core assets.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next